Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immuneering Corp IMRX

Healthcare Biotechnology
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve... see more

Recent & Breaking News (NDAQ:IMRX)

Immuneering Announces Participation in Upcoming Investor Conferences

GlobeNewswire January 24, 2022

Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

GlobeNewswire January 18, 2022

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event

GlobeNewswire January 6, 2022

Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

GlobeNewswire January 3, 2022

Immuneering Added to the Nasdaq Biotechnology Index

GlobeNewswire December 16, 2021

Immuneering Announces Participation in December Investor Conferences

GlobeNewswire November 18, 2021

Immuneering to Participate in Jefferies 2021 London Healthcare Conference

GlobeNewswire November 10, 2021

Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

GlobeNewswire November 9, 2021

Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 11, 2021

Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 1, 2021

Immuneering Announces Inclusion in the Russell 2000® Index

GlobeNewswire September 20, 2021

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

GlobeNewswire September 9, 2021

Immuneering to Participate in September Investor Conferences

GlobeNewswire September 2, 2021

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

GlobeNewswire August 3, 2021

Immuneering Announces Pricing of Upsized Initial Public Offering

GlobeNewswire July 29, 2021